Life Sciences Times, Author at Life Sciences Times

Despite Anti-Vaccine Rhetoric, Global Healthy Living Foundation Sees Strong Interest in Vaccine Education from Chronically Ill Patients

May 9, 2025

Viridian Therapeutics’ Veligrotug Earns FDA Breakthrough Therapy Designation for Thyroid Eye Disease

May 8, 2025

Bain Capital, Botanic Properties Acquire Bedford Site for Biomanufacturing Redevelopment

May 7, 2025

THIS WEEK'S STORIES

eGenesis Appoints Dr. Jay Barth as Chief Medical Officer to Lead Clinical Strategy for Engineered Organ Programs

May 6, 2025

Ansa Biotechnologies Launches Early Access Program for 50 kb Synthetic DNA, Setting New Benchmark in Genomic Research

May 6, 2025

Despite Anti-Vaccine Rhetoric, Global Healthy Living Foundation Sees Strong Interest in Vaccine Education from Chronically Ill Patients

May 9, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

GSK and Lifetime Team Up to Raise Awareness of Meningitis Through New Original Movie

What’s a fair price for a drug that’s never developed?

QuantHealth Launches First Clinical AI Foundation Model for Life Sciences Industry

Despite Anti-Vaccine Rhetoric, Global Healthy Living Foundation Sees Strong Interest in Vaccine Education from Chronically Ill Patients

EDITOR PICKS

Despite Anti-Vaccine Rhetoric, Global Healthy Living Foundation Sees Strong Interest in Vaccine Education from Chronically Ill Patients

Viridian Therapeutics’ Veligrotug Earns FDA Breakthrough Therapy Designation for Thyroid Eye Disease

Bain Capital, Botanic Properties Acquire Bedford Site for Biomanufacturing Redevelopment

THIS WEEK'S STORIES

eGenesis Appoints Dr. Jay Barth as Chief Medical Officer to Lead Clinical Strategy for Engineered Organ Programs

Ansa Biotechnologies Launches Early Access Program for 50 kb Synthetic DNA, Setting New Benchmark in Genomic Research

Despite Anti-Vaccine Rhetoric, Global Healthy Living Foundation Sees Strong Interest in Vaccine Education from Chronically Ill Patients

POPULAR CATEGORY

ABOUT US

FOLLOW US